$Moderna, Inc.(MRNA)$Moderna has previously disclosed that the Phase 3 trial of its ** vaccine candidate mRNA-1273 is expected to begin in July. The trial is still expected to begin in July and we expect to be the first to start a Phase 3 trial. We have worked closely with NIH/OWS to align on the final protocol in order to begin the trial on time.